(Q38873112)

7 September 2017

Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model (English)

1 reference

7 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

hepatocellular carcinoma

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Min-Sun Kwak

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Su Jong Yu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Sung-Hee Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Soo-Mi Lee

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Jeong-Hoon Lee

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Yoon Jun Kim

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Hyo-Suk Lee

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Chung Yong Kim

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

publication date

20 May 2015

1 reference

Journal of Cancer Research and Clinical Oncology

7 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

141

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

2037-2045

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00432-015-1990-6

11 June 2020

exact match

0 references

cites work

Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Population pharmacokinetic data and parameter estimation based on their first two statistical moments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Endoplasmic reticulum stress-induced resistance to doxorubicin is reversed by paeonol treatment in human hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Identification and characterization of a new mammalian glutaredoxin (thioltransferase), Grx2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells toward doxorubicin and phenylarsine oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

MK5 is degraded in response to doxorubicin and negatively regulates doxorubicin-induced apoptosis in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1990-6

Improved chemotherapy for hepatocellular carcinoma.

21 January 2018

1 reference

12 December 2020

Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.

1 reference

12 December 2020

Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.

1 reference

12 December 2020

Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma

1 reference

12 December 2020

N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma.

1 reference

12 December 2020

Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model

1 reference

12 December 2020

Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein

1 reference

12 December 2020

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

1 reference

12 December 2020

Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis.

1 reference

12 December 2020

10.1007/S00432-015-1990-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25989942%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference